According to Daiichi Sankyo’s head of R&D ... bring datopotamab deruxtecan to patients as quickly as possible and mark another step forwards in creating new standards of care for patients ...

The deal with RemeGen gives Seagen a closer rival to AZ and Daiichi Sankyo's Enhertu (trastuzumab ... the drug is predicted to top the $2 billion mark in 2021. Enhertu outperformed Kadcyla at ...

AstraZeneca’s AZN fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus ...

Daiichi Sankyo US continues to redefine the classification and treatment of metastatic breast cancer, and our passion for innovation and compassion for patients brings hope for patients seeking ...

Veteran scientist Hideo Makimura, M.D., Ph.D., is going fully preclinical by joining gene therapy biotech Affinia ...

To recap, NTK in October 2023 filed a lawsuit in the Tokyo District Court alleging that Daiichi Sankyo caused losses by preventing NTK from proceeding with open offers to buy a stake in Indian ...

Exact timing for the debut of the fourth-generation iPhone SE remains up in the air, with Bloomberg's Mark Gurman reporting in a tweet tonight that the device "should be announced by next week." ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Mark J. Alberts, MD, has disclosed the following relevant financial relationships: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee ...

Medical devices comprise electronic equipment, implants, consumables and disposables, surgical instruments and in-vitro diagnostic reagents, among others. Such equipment form a critical part in ...